Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Grand Pharmaceutical Group's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -23.52%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Grand Pharmaceutical Group's 3-Year ROIIC % or its related term are showing as below:
FRA:MX6A's 3-Year ROIIC % is ranked worse than 77.35% of 945
companies
in the Drug Manufacturers industry
Industry Median: 3.57
vs FRA:MX6A: -23.52
Grand Pharmaceutical Group (FRA:MX6A) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Grand Pharmaceutical Group 3-Year ROIIC % Related Terms
Grand Pharmaceutical Group 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grand Pharmaceutical Group 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Grand Pharmaceutical Group's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Grand Pharmaceutical Group (FRA:MX6A) has a 3-Year ROIIC % of -23.52 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Grand Pharmaceutical Group and its competitors. According to the industry distribution chart, Grand Pharmaceutical Group ranks #731 out of 945 companies in the Drug Manufacturers industry, placing it in the top 77.4%.
Is Grand Pharmaceutical Group's 3-Year ROIIC % too high?
Grand Pharmaceutical Group's current 3-Year ROIIC % is -23.52. Based on the distribution chart, Grand Pharmaceutical Group ranks #731 out of 945 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Grand Pharmaceutical Group has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's 3-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Grand Pharmaceutical Group ranks #731 out of 945 companies for 3-Year ROIIC %. This places Grand Pharmaceutical Group in the lower half of its industry. The industry median 3-Year ROIIC % is 3.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.57, based on 945 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Grand Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Pharmaceutical Group's current 3-Year ROIIC % is -23.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Grand Pharmaceutical Group (FRA:MX6A) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.62, compared to a current price of €0.53 — trading 14.5% below its estimated fair value. The current 3-Year ROIIC % is -23.52. Grand Pharmaceutical Group's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Grand Pharmaceutical Group (FRA:MX6A), the current 3-Year ROIIC % is -23.52 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grand Pharmaceutical Group (FRA:MX6A) Overvalued in 2026?
Based on GuruFocus' analysis, Grand Pharmaceutical Group stock appears to be undervalued.
The current stock price of €0.53 is trading 14.5% below its estimated GF Value™ of €0.62.
GuruFocus considers Grand Pharmaceutical Group to be Modestly Undervalued.
Key valuation signals for FRA:MX6A:
3-Year ROIIC %: -23.52
GF Value™: €0.62 vs. price of €0.53 (14.5% below fair value)
No single metric tells the full story. See the FRA:MX6A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
88GF Score
Get the complete analysis for FRA:MX6A
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MX6A has been successfully added to your 
